145 related articles for article (PubMed ID: 35019820)
21. Targeting ZFP64/GAL-1 axis promotes therapeutic effect of nab-paclitaxel and reverses immunosuppressive microenvironment in gastric cancer.
Zhu M; Zhang P; Yu S; Tang C; Wang Y; Shen Z; Chen W; Liu T; Cui Y
J Exp Clin Cancer Res; 2022 Jan; 41(1):14. PubMed ID: 34996504
[TBL] [Abstract][Full Text] [Related]
22. Differential combination immunotherapy requirements for inflamed (warm) tumors versus T cell excluded (cool) tumors: engage, expand, enable, and evolve.
Fabian KP; Padget MR; Fujii R; Schlom J; Hodge JW
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33602696
[TBL] [Abstract][Full Text] [Related]
23. A novel multifunctional anti-CEA-IL15 molecule displays potent antitumor activities.
Liu Y; Wang Y; Xing J; Li Y; Liu J; Wang Z
Drug Des Devel Ther; 2018; 12():2645-2654. PubMed ID: 30214153
[TBL] [Abstract][Full Text] [Related]
24. Nab-paclitaxel is an active drug in preclinical model of pediatric solid tumors.
Zhang L; Marrano P; Kumar S; Leadley M; Elias E; Thorner P; Baruchel S
Clin Cancer Res; 2013 Nov; 19(21):5972-83. PubMed ID: 23989978
[TBL] [Abstract][Full Text] [Related]
25. Nab-paclitaxel interrupts cancer-stromal interaction through C-X-C motif chemokine 10-mediated interleukin-6 downregulation in vitro.
Feng R; Morine Y; Ikemoto T; Imura S; Iwahashi S; Saito Y; Shimada M
Cancer Sci; 2018 Aug; 109(8):2509-2519. PubMed ID: 29902349
[TBL] [Abstract][Full Text] [Related]
26. Superior antitumor activity of nanoparticle albumin-bound paclitaxel in experimental gastric cancer.
Zhang C; Awasthi N; Schwarz MA; Hinz S; Schwarz RE
PLoS One; 2013; 8(2):e58037. PubMed ID: 23460921
[TBL] [Abstract][Full Text] [Related]
27. Lipoteichoic acid of Bifidobacterium in combination with 5-fluorouracil inhibit tumor growth and relieve the immunosuppression.
Xie N; Wang Y; Wang Q; Li FR; Guo B
Bull Cancer; 2012 May; 99(5):E55-63. PubMed ID: 22522606
[TBL] [Abstract][Full Text] [Related]
28. Colorectal cancer cell-derived CCL20 recruits regulatory T cells to promote chemoresistance via FOXO1/CEBPB/NF-κB signaling.
Wang D; Yang L; Yu W; Wu Q; Lian J; Li F; Liu S; Li A; He Z; Liu J; Sun Z; Yuan W; Zhang Y
J Immunother Cancer; 2019 Aug; 7(1):215. PubMed ID: 31395078
[TBL] [Abstract][Full Text] [Related]
29. Determination of a CD4
Jafarinia M; Mehdipour F; Hosseini SV; Ghahramani L; Hosseinzadeh M; Ghaderi A
Tumour Biol; 2016 Nov; 37(11):14659-14666. PubMed ID: 27619682
[TBL] [Abstract][Full Text] [Related]
30. Microspheres Encapsulating Immunotherapy Agents Target the Tumor-Draining Lymph Node in Pancreatic Ductal Adenocarcinoma.
Han BJ; Murphy JD; Qin S; Ye J; Uccello TP; Garrett-Larsen J; Belt BA; Prieto PA; Egilmez NK; Lord EM; Linehan DC; Mills BN; Gerber SA
Immunol Invest; 2020 Oct; 49(7):808-823. PubMed ID: 32498585
[TBL] [Abstract][Full Text] [Related]
31. The application of nanoparticles in cancer immunotherapy: Targeting tumor microenvironment.
Yang M; Li J; Gu P; Fan X
Bioact Mater; 2021 Jul; 6(7):1973-1987. PubMed ID: 33426371
[TBL] [Abstract][Full Text] [Related]
32. Synergistic effects of IL-12 and IL-18 in skewing tumor-reactive T-cell responses towards a type 1 pattern.
Li Q; Carr AL; Donald EJ; Skitzki JJ; Okuyama R; Stoolman LM; Chang AE
Cancer Res; 2005 Feb; 65(3):1063-70. PubMed ID: 15705908
[TBL] [Abstract][Full Text] [Related]
33. Neutralization of TNFα in tumor with a novel nanobody potentiates paclitaxel-therapy and inhibits metastasis in breast cancer.
Ji X; Peng Z; Li X; Yan Z; Yang Y; Qiao Z; Liu Y
Cancer Lett; 2017 Feb; 386():24-34. PubMed ID: 27832973
[TBL] [Abstract][Full Text] [Related]
34. Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model.
Yu P; Steel JC; Zhang M; Morris JC; Waitz R; Fasso M; Allison JP; Waldmann TA
Proc Natl Acad Sci U S A; 2012 Apr; 109(16):6187-92. PubMed ID: 22474386
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of PD-1 blockade in cervical cancer is related to a CD8
Heeren AM; Rotman J; Stam AGM; Pocorni N; Gassama AA; Samuels S; Bleeker MCG; Mom CH; Zijlmans HJMAA; Kenter GG; Jordanova ES; de Gruijl TD
J Immunother Cancer; 2019 Feb; 7(1):43. PubMed ID: 30755279
[TBL] [Abstract][Full Text] [Related]
36. Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy.
Knudson KM; Hicks KC; Alter S; Schlom J; Gameiro SR
J Immunother Cancer; 2019 Mar; 7(1):82. PubMed ID: 30898149
[TBL] [Abstract][Full Text] [Related]
37. Enhancement of adoptive T cell transfer with single low dose pretreatment of doxorubicin or paclitaxel in mice.
Hsu FT; Chen TC; Chuang HY; Chang YF; Hwang JJ
Oncotarget; 2015 Dec; 6(42):44134-50. PubMed ID: 26683520
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic efficacy of anti-MMP9 antibody in combination with nab-paclitaxel-based chemotherapy in pre-clinical models of pancreatic cancer.
Awasthi N; Mikels-Vigdal AJ; Stefanutti E; Schwarz MA; Monahan S; Smith V; Schwarz RE
J Cell Mol Med; 2019 Jun; 23(6):3878-3887. PubMed ID: 30941918
[TBL] [Abstract][Full Text] [Related]
39. The synergistic antitumor activity of 3-(2-nitrophenyl) propionic acid-paclitaxel nanoparticles (NPPA-PTX NPs) and anti-PD-L1 antibody inducing immunogenic cell death.
Duan XC; Peng LY; Yao X; Xu MQ; Li H; Zhang SQ; Li ZY; Wang JR; Feng ZH; Wang GX; Liao A; Chen Y; Zhang X
Drug Deliv; 2021 Dec; 28(1):800-813. PubMed ID: 33866918
[TBL] [Abstract][Full Text] [Related]
40. Enhancing intratumoral biodistribution and antitumor activity of nab-paclitaxel through combination with a vascular disrupting agent, combretastatin A-4-phosphate.
Gao M; Zhang D; Yao N; Jin Q; Jiang C; Zhang J; Wang F
Cancer Chemother Pharmacol; 2019 Dec; 84(6):1187-1194. PubMed ID: 31520101
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
